Article PDF
Literatur
Mitteilung der Ständigen Impfkommission (STIKO) am Robert Koch-Institut: Hinweise zu Impfungen für Patienten mit Immundefizienz, Sonderdruck (2005).
Valour F, Cotte L, Voirin N, Godinot M, Ader F, Ferry T et al (2014) Vaccination coverage against hepatitis A and B viruses, Streptococcus pneumoniae, seasonal flu, and A(H1N1)2009 pandemic influenza in HIV-infected patients. Vaccine 32(35:4558–4564
Grabmeier-Pfistershammer K, Herkner H, Touzeau-Roemer V, Rieger A, Burgmann H, Poeppl W (2015) Low tetanus, diphtheria and acellular pertussis (Tdap) vaccination coverage among HIV infected individuals in Austria. Vaccine 33(32):3929–3932
Loubet P, Kerneis S, Groh M, Loulergue P, Blanche P, Verger P et al (2015) Attitude, knowledge and factors associated with influenza and pneumococcal vaccine uptake in a large cohort of patients with secondary immune deficiency. Vaccine 33(31):3703–3708
Durham MD, Buchacz K, Armon C, Patel P, Wood K, Brooks JT (2011) Rates and correlates of influenza vaccination among HIV-infected adults in the HIV Outpatient Study (HOPS), USA, 1999-2008. Prev Med 53(1-2:89–94
Orange JS, Ballow M, Stiehm ER, Ballas ZK, Chinen J, De La Morena M et al (2012) Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol 130:S1–S24
Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M et al (2014) 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 58(3:309–318
Committee to Review Adverse Effects of V, Institute of M. In: Stratton K, Ford A, Rusch E, Clayton EW, editors. Adverse Effects of Vaccines: Evidence and Causality. Washington (DC): National Academies Press (US) Copyright 2012 by the National Academy of Sciences. All rights reserved.; 2011.
Fine PEM (1993) Herd immunity: history, theory, practice. Epidemiol Rev 15:265–302
Anderson RM, May RM (1991) Infectious Diseases of Humans: Dynamics and Control. University Press, Oxford
Ständigen Impfkommission (STIKO) am Robert Koch-Institut (2016) 2017. Epidemiol Bull 2016:34
Shearer WT, Fleisher TA, Buckley RH, Ballas Z, Ballow M, Blaese RM et al (2014) Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts. J Allergy Clin Immunol 133(4):961–966
Esposito S, Prada E, Lelii M, Castellazzi L (2015) Immunization of children with secondary immunodeficiency. Hum Vaccin Immunother 11(11):2564–2570
Principi N, Esposito S (2014) Vaccine use in primary immunodeficiency disorders. Vaccine 32(30):3725–3731
Aguilar C, Malphettes M, Donadieu J, Chandesris O, Coignard-Biehler H, Catherinot E et al (2014) Prevention of infections during primary immunodeficiency. Clin Infect Dis 59(10):1462–1470
Farmand S, Baumann U, von Bernuth H, Borte M, Foerster-Waldl E, Franke K et al (2011) Interdisciplinary AWMF guideline for the diagnostics of primary immunodeficiency. Klin Padiatr 223(6):378–385
Netea MG, Joosten LA, Latz E, Mills KH, Natoli G, Stunnenberg HG et al (2016) Trained immunity: A program of innate immune memory in health and disease. Science 352(6284):aaf1098
Warfel JM, Edwards KM (2015) Pertussis vaccines and the challenge of inducing durable immunity. Curr Opin Immunol 35:48–54
Pollard AJ, Perrett KP, Beverley PC (2009) Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 9(3):213–220
Mitchell R, Kelly DF, Pollard AJ, Truck J (2014) Polysaccharide-specific B cell responses to vaccination in humans. Hum Vaccin Immunother 10(6):1661–1668
McKelvie B, Top K, McCusker C, Letenyi D, Issekutz TB, Issekutz AC (2014) Fatal pneumococcal meningitis in a 7-year-old girl with interleukin-1 receptor activated kinase deficiency (IRAK-4) despite prophylactic antibiotic and IgG responses to Streptococcus pneumoniae vaccines. J Clin Immunol 34(3):267–271
Poolman J, Borrow R (2011) Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. Expert Rev Vaccines 10(3):307–322
Remschmidt CHT, Wichmann O, Bogdan C, Falkenhorst G (2017) Effectiveness, immunogenicity and safety of revaccinations with the 23-valent pneumococcal polysaccharide vaccine in the elderly: a systematic review. Bmc Infect Dis 16(1):711
Falkenhorst GRC, Harder T, Wichmann O, Glodny S, Hummers-Pardier E, von Kries R, Weinke T, Ledig T, Bogdan C (2017) Background paper to the updated pneumococcal vaccination recommendation for older adults in Germany. Bundesgesundheitsblatt 59(12):1623–1657
Kobrynski L (2015) Newborn screening for severe combined immune deficiency (technical and political aspects). Curr Opin Allergy Clin Immunol 15(6):539–546
Buelow BJ, Verbsky JW, Routes JM (2016) Newborn screening for SCID: lessons learned. Expert Rev Hematol 9(6):579–584
Siegrist CA, Aspinall R (2009) B-cell responses to vaccination at the extremes of age. Nat Rev Immunol 9(3):185–194
Newport MJ, Goetghebuer T, Weiss HA, Whittle H, Siegrist CA, Marchant A et al (2004) Genetic regulation of immune responses to vaccines in early life. Genes Immun 5(2):122–129
Whaley MJ, Rose C, Martinez J, Laher G, Sammons DL, Smith JP et al (2010) Interlaboratory comparison of three multiplexed bead-based immunoassays for measuring serum antibodies to pneumococcal polysaccharides. Clin Vaccine Immunol 17(5):862–869
Björkholm B, Bottiger M, Christenson B, Hagberg L (1986) Antitoxin antibody levels and the outcome of illness during an outbreak of diphtheria among alcoholics. Scand J Infect Dis 18(3):235-239
Bigl S, Drechsler R (1997) Bestimmung von Diphterieantitoxin im Serum - ein Methodenvergleich. Mikrobiologie :93–95
Lumio JT et al (2003) What is a protective level of diphtheria antitoxin antibodies? Abstract 43rd Intersci Conf Antimicr Agents Chemother
Fiore AE, Finestone SM, Bell BP (2008) Vaccine, Elsevier, Philadelphia, S 177–203
Jack AD, Hall AJ, Maine N, Mendy M, Whittle HC (1999) What level of hepatitis B antibody is protective? J Infect Dis 179(2):489–492
Kayhty H (1994) Difficulties in establishing a serological correlate of protection after immunization with Haemophilus influenzae conjugate vaccines. Biologicals 22(4):397–402
Zepp F, Schmitt HJ, Cleerbout J, Verstraeten T, Schuerman L, Jacquet JM (2009) Review of 8 years of experience with Infanrix hexa (DTPa-HBV-IPV/Hib hexavalent vaccine). Expert Rev Vaccines 8(6):663–678
Chen RT, Markowitz LE, Albrecht P, Stewart JA, Mofenson LM, Preblud SR et al (1990) Measles antibody: reevaluation of protective titers. J Infect Dis 162(5):1036–1042
Weibel RE, Buynak EB, McLean AA, Hilleman MR (1995) Long-term follow-up for immunity after monovalent or combined live measles, mumps, and rubella virus vaccines. Pediatrics 56:380–387
Würzburg RU. http://www.meningococcus.uni-wuerzburg.de/startseite/leistungen/leistungen_meningokokken/. Zugegriffen: 12. Dezember 2016
MacNeil J, al. e (2015) Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015. Morb Mortal Wkly Rep 64(41):1171–1176
Jodar L, Butler J, Carlone G, Dagan R, Goldblatt D, Kayhty H et al (2003) Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 21(23):3265–3272
Siber GR, Chang I, Baker S, Fernsten P, O'Brien KL, Santosham M et al (2007) Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine 25(19):3816–3826
Faden H, Modlin JF, Thoms ML, McBean AM, Ferdon MB, Ogra PL (1990) Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. J Infect Dis 162(6):1291–1297
Matter L, Kogelschatz K, Germann D (1997) Serum levels of rubella virus antibodies indicating immunity: response to vaccination of subjects with low or undetectable antibody concentrations. J Infect Dis 175(4):749–755
Sauerbrei A, Schafler A, Hofmann J, Schacke M, Gruhn B, Wutzler P (2012) Evaluation of three commercial varicella-zoster virus IgG enzyme-linked immunosorbent assays in comparison to the fluorescent-antibody-to-membrane-antigen test. Clin Vaccine Immunol 19(8):1261–1268
Sauerbrei A, Farber I, Brandstadt A, Schacke M, Wutzler P (2004) Immunofluorescence test for sensitive detection of varicella-zoster virus-specific IgG: an alternative to fluorescent antibody to membrane antigen test. J Virol Methods 119(1):25–30
Sauerbrei A, Prager J, Hengst U, Zintl F, Wutzler P (1997) Varicella vaccination in children after bone marrow transplantation. Bone Marrow Transplant 20(5):381–383
Plotkin SA (2010) Correlates of protection induced by vaccination. Clin Vaccine Immunol 17(7):1055–1065
Morillo-Gutierrez B, Worth A, Valappil M, Gaspar HB, Gennery AR (2015) Chronic Infection with Rotavirus Vaccine Strains in UK Children with Severe Combined Immunodeficiency. Pediatr Infect Dis J 34(9):1040–1041
Perelygina L, Plotkin S, Russo P, Hautala T, Bonilla F, Ochs HD et al (2016) Rubella persistence in epidermal keratinocytes and granuloma M2 macrophages in patients with primary immunodeficiencies. J Allergy Clin Immunol 138(5):1436–1439.e1
Neven B, Perot P, Bruneau J, Pasquet M, Ramirez M, Diana JS et al (2017) Cutaneous and Visceral Chronic Granulomatous Disease Triggered by a Rubella Virus Vaccine Strain in Children With Primary Immunodeficiencies. Clin Infect Dis 64(1):83–86
Bitnun A, Shannon P, Durward A, Rota PA, Bellini WJ, Graham C et al (1999) Measles inclusion-body encephalitis caused by the vaccine strain of measles virus. Clin Infect Dis 29(4):855–861
Iroh TP (2014) Measles vaccine strain from the skin rash of a DiGeorge patient receiving tumor necrosis factor inhibitor. Pediatr Infect Dis J 33(1):117
CDC (1996) Measles pneumonitis following measles-mumps-rubella vaccination of a patient with HIV infection, 1993. MMWR Morb Mortal Wkly Rep 45(28):603–606
Leung J, Siegel S, Jones JF, Schulte C, Blog D, Schmid DS et al (2014) Fatal varicella due to the vaccine-strain varicella-zoster virus. Hum Vaccin Immunother 10(1):146–149
Bayer DK, Martinez CA, Sorte HS, Forbes LR, Demmler-Harrison GJ, Hanson IC et al (2014) Vaccine-associated varicella and rubella infections in severe combined immunodeficiency with isolated CD4 lymphocytopenia and mutations in IL7R detected by tandem whole exome sequencing and chromosomal microarray. Clin Exp Immunol 178(3):459–469
Dutmer CM, Asturias EJ, Smith C, Dishop MK, Schmid DS, Bellini WJ et al (2015) Late Onset Hypomorphic RAG2 Deficiency Presentation with Fatal Vaccine-Strain VZV Infection. J Clin Immunol 35(8):754–760
Sabry A, Hauk PJ, Jing H, Su HC, Stence NV, Mirsky DM et al (2014) Vaccine strain varicella-zoster virus-induced central nervous system vasculopathy as the presenting feature of DOCK8 deficiency. J Allergy Clin Immunol 133(4):1225–1227
Banovic T, Yanilla M, Simmons R, Robertson I, Schroder WA, Raffelt NC et al (2011) Disseminated varicella infection caused by varicella vaccine strain in a child with low invariant natural killer T cells and diminished CD1d expression. J Infect Dis 204(12):1893–1901
Waters V, Peterson KS, LaRussa P (2007) Live viral vaccines in a DiGeorge syndrome patient. Arch Dis Child 92(6):519–520
Schrauder A, Henke-Gendo C, Seidemann K, Sasse M, Cario G, Moericke A et al (2007) Varicella vaccination in a child with acute lymphoblastic leukaemia. Lancet 369(9568):1232
Costa E, Buxton J, Brown J, Templeton KE, Breuer J, Johannessen I (2016) Fatal disseminated varicella zoster infection following zoster vaccination in an immunocompromised patient. BMJ Case Rep. doi: 10.1136/bcr-2015-212688
Bhalla P, Forrest GN, Gershon M, Zhou Y, Chen J, LaRussa P et al (2015) Disseminated, persistent, and fatal infection due to the vaccine strain of varicella-zoster virus in an adult following stem cell transplantation. Clin Infect Dis 60(7):1068–1074
Guo J, Bolivar-Wagers S, Srinivas N, Holubar M, Maldonado Y (2015) Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: a systematic review and implications for polio eradication. Vaccine 33(10):1235–1242
de Silva R, Gunasena S, Ratnayake D, Wickremesinghe GD, Kumarasiri CD, Pushpakumara BA et al (2012) Prevalence of prolonged and chronic poliovirus excretion among persons with primary immune deficiency disorders in Sri Lanka. Vaccine 30(52):7561–7565
Shaghaghi M, Parvaneh N, Ostad-Rahimi P, Fathi SM, Shahmahmoodi S, Abolhassani H et al (2014) Combined immunodeficiency presenting with vaccine-associated paralytic poliomyelitis: a case report and narrative review of literature. Immunol Invest 43(3):292–298
Trimble R, Atkins J, Quigg TC, Burns CC, Wallace GS, Thomas M et al (2014) Vaccine-associated paralytic poliomyelitis and BCG-osis in an immigrant child with severe combined immunodeficiency syndrome - Texas, 2013. MMWR Morb Mortal Wkly Rep 63(33:721–724
Canessa C, Romano F, Lippi F, Bianchi L, Kashef S, Rezaei N et al (2013) Bcgitis and vaccine-derived poliovirus infection in a patient with a novel deletion in RAG1 binding site. Int J Immunopathol Pharmacol 26(2):511–515
Seligman SJ (2014) Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD). Vaccine 32(44):5769–5775
Thomas RE, Lorenzetti DL, Spragins W, Jackson D, Williamson T (2012) The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: systematic review. Am J Trop Med Hyg 86(2):359–372
Monath TP (2012) Review of the risks and benefits of yellow fever vaccination including some new analyses. Expert Rev Vaccines 11(4):427–448
Traiber C (2011) Infant meningoencephalitis caused by yellow fever vaccine virus transmitted via breastmilk. J Pediatr (Rio J) 87(3):269–272
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Niehues, T., Bogdan, C., Hecht, J. et al. Impfen bei Immundefizienz. Bundesgesundheitsbl 60, 674–684 (2017). https://doi.org/10.1007/s00103-017-2555-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00103-017-2555-4